NASDAQ:ABVC

Abvc Biopharma Stock Insider Trading

Healthcare > Biotechnology

Buy ABVC

*Your capital is at risk

$1.28

+0.0300 (+2.40%)

At Close: Jun 03, 2026

ABVC BioPharma Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at 0. In total, the insiders bought 48.54M and sold 8.7M ABVC shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	0
● Buy	48.54M shares
● Sell	8.7M shares
94% Buy Activity Negligible or No Correlation
No Significant Signals No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jun 29, 2010 Buy	Convertible Preferred Shares, Series B	Juliano James Director	Director	10 054 371 Value: $502.7K
Jun 29, 2010 Buy	Convertible Preferred Shares, Series A	Juliano James Director	Director	4 994 000 Value: $2.50M
Jun 29, 2010 Buy	Common Stock	Juliano James Director	Director	0 Value: $0
Jun 29, 2010 Buy	Common Stock	Juliano James Director	Director	0 Value: $0
Jun 29, 2010 Buy	Convertible Preferred Shares, Series A	Juliano James Director	Director	4 994 000 Value: $2.50M
Jun 29, 2010 Buy	Convertible Preferred Shares, Series B	Juliano James Director	Director	10 054 371 Value: $502.7K
Jun 29, 2010 Buy	Common Stock J-Other	Delmonaco, Jr. Rocco	Director	0 Value: $0
Jun 29, 2010 Buy	Common Stock J-Other	Smith J.b.	Director	0 Value: $0
May 11, 2010 Buy	Common Stock P-Purchase	Nirta Joseph Director	Director	10 000 Value: $2K
May 11, 2010 Buy	Common Stock P-Purchase	Nirta Joseph Director	Director	10 000 Value: $2K
Mar 23, 2010 Buy	Options to acquire common stock A-Award	Iannotti Daniel V Vp, General Counsel & Secretar	Officer	220 000 Value: $112.2K
Mar 23, 2010 Buy	Options to acquire common stock A-Award	Iannotti Daniel V Vp, General Counsel & Secretar	Officer	220 000 Value: $112.2K
Mar 22, 2010 Buy	Common Stock P-Purchase	Nirta Joseph Director	Director	2 000 Value: $520
Mar 22, 2010 Buy	Common Stock P-Purchase	Nirta Joseph Director	Director	2 000 Value: $520
Jan 13, 2010 Buy	Convertible Preferred Shares, Series B P-Purchase	Smith J.b.	Director	55 Value: $3
Jan 13, 2010 Buy	Convertible Preferred Shares, Series B P-Purchase	Smith J.b.	Director	55 Value: $3
Dec 16, 2009 Buy	Convertible preferred shares, Series B P-Purchase	Smith J.b.	Director	31 Value: $2
Dec 16, 2009 Buy	Convertible preferred shares, Series B P-Purchase	Smith J.b.	Director	31 Value: $2
Nov 13, 2009 Buy	Common Stock P-Purchase	Smith J.b.	Director	714 286 Value: $35.7B
Nov 13, 2009 Buy	Common Stock P-Purchase	Smith J.b.	Director	714 286 Value: $35.7B
Oct 02, 2009 Buy	Warrant No. 1 P-Purchase	Stromback Richard Dean 10 Percent Owner	10% Owner	14 400 Value: $6K
Oct 02, 2009 Buy	Warrant No. 1 P-Purchase	Stromback Richard Dean 10 Percent Owner	10% Owner	14 400 Value: $6K
Oct 01, 2009 Buy	Preferred Shares P-Purchase	Stromback Richard Dean 10 Percent Owner	10% Owner	240 Value: $101
Oct 01, 2009 Buy	Preferred Shares P-Purchase	Stromback Richard Dean 10 Percent Owner	10% Owner	240 Value: $101
Sep 21, 2009 Buy	Common Stock A-Award	Iannotti Daniel V Vp, General Counsel & Secretar	Officer	70 000 Value: $35.7K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT ABVC BIOPHARMA, INC.

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity d...

Read Full Profile Here